467 related articles for article (PubMed ID: 33187148)
21. EPCAM and TROP2 share a role in claudin stabilization and development of intestinal and extraintestinal epithelia in mice.
Szabo R; Ward JM; Artunc F; Bugge TH
Biol Open; 2022 Jul; 11(7):. PubMed ID: 35730316
[TBL] [Abstract][Full Text] [Related]
22. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.
Shvartsur A; Bonavida B
Genes Cancer; 2015 Mar; 6(3-4):84-105. PubMed ID: 26000093
[TBL] [Abstract][Full Text] [Related]
23. TROP2 methylation and expression in tamoxifen-resistant breast cancer.
Zimmers SM; Browne EP; Williams KE; Jawale RM; Otis CN; Schneider SS; Arcaro KF
Cancer Cell Int; 2018; 18():94. PubMed ID: 30002602
[TBL] [Abstract][Full Text] [Related]
24. Amelioration of Congenital Tufting Enteropathy in EpCAM (TROP1)-Deficient Mice via Heterotopic Expression of TROP2 in Intestinal Epithelial Cells.
Nakato G; Morimura S; Lu M; Feng X; Wu C; Udey MC
Cells; 2020 Aug; 9(8):. PubMed ID: 32781650
[TBL] [Abstract][Full Text] [Related]
25. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
Jeon Y; Jo U; Hong J; Gong G; Lee HJ
BMC Cancer; 2022 Sep; 22(1):1014. PubMed ID: 36153494
[TBL] [Abstract][Full Text] [Related]
26. Trop2: from development to disease.
McDougall AR; Tolcos M; Hooper SB; Cole TJ; Wallace MJ
Dev Dyn; 2015 Feb; 244(2):99-109. PubMed ID: 25523132
[TBL] [Abstract][Full Text] [Related]
27. Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
Lombardi P; Filetti M; Falcone R; Altamura V; Paroni Sterbini F; Bria E; Fabi A; Giannarelli D; Scambia G; Daniele G
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980630
[TBL] [Abstract][Full Text] [Related]
28. A New in Vitro Model of GDLD by Knocking Out
Xu P; Kai C; Kawasaki S; Kobayashi Y; Yamamoto K; Tsujikawa M; Hayashi R; Nishida K
Transl Vis Sci Technol; 2018 Nov; 7(6):30. PubMed ID: 30619650
[TBL] [Abstract][Full Text] [Related]
29. TACSTD2 upregulation is an early reaction to lung infection.
Lenárt S; Lenárt P; Knopfová L; Kotasová H; Pelková V; Sedláková V; Vacek O; Pokludová J; Čan V; Šmarda J; Souček K; Hampl A; Beneš P
Sci Rep; 2022 Jun; 12(1):9583. PubMed ID: 35688908
[TBL] [Abstract][Full Text] [Related]
30. Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma.
Sawanyawisuth K; Tantapotinan N; Wongkham C; Riggins GJ; Kraiklang R; Wongkham S; Puapairoj A
Ann Hepatol; 2016; 15(1):71-81. PubMed ID: 26626643
[TBL] [Abstract][Full Text] [Related]
31. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
Zhao M; DiPeri TP; Raso MG; Zheng X; Rizvi YQ; Evans KW; Yang F; Akcakanat A; Roberto Estecio M; Tripathy D; Dumbrava EE; Damodaran S; Meric-Bernstam F
NPJ Breast Cancer; 2023 Aug; 9(1):66. PubMed ID: 37567892
[TBL] [Abstract][Full Text] [Related]
32. TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial-Mesenchymal Transition and Invasiveness.
Švec J; Šťastná M; Janečková L; Hrčkulák D; Vojtěchová M; Onhajzer J; Kříž V; Galušková K; Šloncová E; Kubovčiak J; Pfeiferová L; Hrudka J; Matěj R; Waldauf P; Havlůj L; Kolář M; Kořínek V
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077674
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
34. TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer.
Liu X; Zhou T; Wang Y; Pei M; Wang G; Chu W; Wang Q; Du S; Wang H; Wang C
Onco Targets Ther; 2022; 15():509-520. PubMed ID: 35535168
[TBL] [Abstract][Full Text] [Related]
35. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
36. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma.
Wang J; Zhang K; Grabowska D; Li A; Dong Y; Day R; Humphrey P; Lewis J; Kladney RD; Arbeit JM; Weber JD; Chung CH; Michel LS
Mol Cancer Res; 2011 Dec; 9(12):1686-95. PubMed ID: 21970857
[TBL] [Abstract][Full Text] [Related]
37. Trop2 Forms a Stable Dimer with Significant Structural Differences within the Membrane-Distal Region as Compared to EpCAM.
Pavšič M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638982
[TBL] [Abstract][Full Text] [Related]
38. Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors.
Menz A; Lony N; Lennartz M; Dwertmann Rico S; Schlichter R; Kind S; Reiswich V; Viehweger F; Dum D; Luebke AM; Kluth M; Gorbokon N; Hube-Magg C; Bernreuther C; Simon R; Clauditz TS; Sauter G; Hinsch A; Jacobsen F; Marx AH; Steurer S; Minner S; Burandt E; Krech T; Lebok P; Weidemann S
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786342
[TBL] [Abstract][Full Text] [Related]
39. Ginsenoside Rb3 Alleviates CSE-induced TROP2 Upregulation through p38 MAPK and NF-κB Pathways in Basal Cells.
Li H; Cui L; Liu Q; Dou S; Wang W; Xie M; Xu X; Zheng C; Li T; Huang S; Cui X; Xiao W
Am J Respir Cell Mol Biol; 2021 Jun; 64(6):747-759. PubMed ID: 33705682
[TBL] [Abstract][Full Text] [Related]
40. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
